Intravascular plasmid DNA (pDNA) vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) effectively induces prophylactic immunity against lethal HSV-1 infection in mice. We investigated whether the vaccine potency is further improved by coadministration of cytokine genes together with a low dose of genetic vaccine. pDNA encoding IL-12, IL-15, IL-18 or IL-21 was capable of elevating survival rates of HSV-1-infected mice when coinjected with 1 mg of gB pDNA, while IL-10 gene delivery failed to affect the effectiveness of the genetic immunization. Although only 17% of mice survived acute HSV infection after the gB pDNA vaccination at a dose of 1 mg, all mice coadministered with 1 mg each of gB and IL-12 pDNAs not only survived the acute infection but also escaped latent infection. In these animals, the neutralizing antibody against HSV-1 was abundantly produced, and CTL activity against the gB antigen was augmented. Coadministration of the gB and IL-12 genes also elevated the serum level of interferon-g. Adaptive transfer experiments indicated that soluble factors contributed to preventive immunity, while cell components alone were not capable of protecting mice from fatal viral infection. These results strongly suggest potential usefulness of Th1 cytokine genes as effective molecular adjuvants that facilitate specific humoral as well as cellular immune responses elicited by intravascular molecular vaccination.
Introduction
Genetic immunization is a promising measure to prevent life-threatening or highly distressing infectious diseases. In most of the earlier studies on genetic immunization, skeletal muscle was considered as the target organ to be immunized with naked plasmid DNA (pDNA) vaccine. In murine acute herpes simplex virus (HSV) infection model, pDNA encoding glycoproteins B (gB) [1] [2] [3] [4] [5] or D (gD) 2, [5] [6] [7] [8] was repetitively injected into the skeletal muscle of mice, resulting in significant protective outcome against subsequent intraperitoneal, 2,7,8 intradermal, 1, 5 vaginal 3, 6 or foot pad 4 challenge of the virus. The treatments predominantly induced antigen-specific antibody production, while activation of virus-specific CTL has not been demonstrated unless some adjuvant was coadministered. In contrast, intranasal immunization with the gB gene induced IgA mucosal immunity rather than systemic humoral response, and protective activity against lethal challenge was not evident. 3, 9 Therefore, the routes of administration are crucial for the types of immune responses to be induced. We previously attempted intravascular gB gene transfection into mice, because extremely strong and prolonged expression of exogenous genes is achieved in vivo by means of this technology. [10] [11] [12] As a result, the animals were highly resistant to a subsequent lethal HSV-1 challenge. 13 The surviving mice also escaped latent infection, which was not reported in earlier studies using intramuscular pDNA vaccination. The intravascular pDNA vaccine induced not only humoral but also CTL responses. Therefore, we concluded that this procedure may offer a feasible method to control infectious diseases, provided that further modification and improvement of the system were made.
It has been demonstrated that intramuscular or intranasal delivery of various cytokine genes promotes antigenspecific immunity triggered by a genetic vaccine for a pathogen. pDNAs encoding interferon (IFN)-g, 14 IL-2, [15] [16] [17] IL-12, 9,14,17-20 IL-15, 21 IL-18 9, 22 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 15, 17, 19 have been shown to enhance Th1 immune responses triggered by a pDNA vaccine against human immunodeficiency (HIV) virus, [15] [16] [17] 19, 21 hepatitis B virus, 14 mycobacterium 20 and HSV, 9, 18, 22 although the humoral response was elevated 9, [14] [15] [16] [17] 19 or downmodulated, 15, 18, 20, 21 depending on the cytokines and antigens employed. In some reports, the use of cytokine genes brought significant elevation in CTL activities against the antigens. [14] [15] [16] [17] 19, 21 The results strongly suggest the potential usefulness of the cytokine gene delivery as molecular adjuvants.
We postulated that the adjuvant activity of cytokines may also be enhanced when the cytokine genes are delivered to animals through intravascular injections, and the treatments may greatly improve the efficacy of the intravascular pDNA vaccine. In the present study, various cytokine genes including IL-12 p35 and p40 cDNAs were codelivered with the HSV-1 gB gene into mice to assess whether the immune protection against fatal herpetic lesions is improved under the influence of the molecular adjuvants. Anti-HSV immune responses modulated by IL-12 gene delivery are also analyzed.
Results
Intravascular gB gene immunization together with cytokine gene administration protected mice from lethal HSV-1 challenge
We previously showed that two times intravascular administration of 5 and 3 mg of pGEG.gB protected 83 and 67% of mice from lethal HSV-1 challenge, respectively, while only 17% of HSV-1-infected mice survived after vaccination with 1 mg of the plasmid. 13 To examine whether coadministration with immunomodulatory cytokine genes further improved the prophylactic effect of the pDNA vaccine, mice were injected twice with 1 mg of pGEG.gB, singly or in combination with 1 mg of expression vector plasmid encoding IL-10, IL-12, IL-15, IL-18 or IL-21. Following systemic inoculation with a lethal dose of HSV-1, all the control mice that had been left untreated or sham-immunized with saline died by day 9 (Figure 1 (Figure 1b ). All the mice that received a mixture of pGEG.gB and pGEG.mIL-12 were rendered unsusceptible to the fatal HSV-1 infection (Figure 1a) , whereas pDNA encoding IL-10, a Th2 cytokine, failed to Genetic adjuvant for intravascular pDNA vaccine F-D Cui et al significantly affect the mortality of the gB gene-immunized mice after HSV infection (Figure 1b ). All the mice vaccinated with gB and/or cytokine plasmids did not show any sign of toxic effects. We examined whether the gB plus IL-12 genetic treatment also protected mice from the latent infection that is commonly seen in the sensory ganglia after acute HSV-1 infection. As shown in Figures 2 and 3 , the HSV gD sequence was not amplified by PCR analyses of the DNA collected from trigeminal ganglia, cerebrum, cerebellum and dorsal root ganglia of the animals that survived the lethal HSV infection owing to the gB plus IL-12 genes. The results showed that all the mice escaped latent infection after the coadministration of the molecular vaccine and adjuvant. In contrast, latent infection was demonstrated in the mouse that survived lethal HSV infection after gB plus IL-10 genetic vaccination ( Figure  3a, lane 7) .
Induction of anti-HSV-1 neutralizing antibodies
Next we investigated the immune responses against HSV-1 that were generated by the IL-12 plus genetic vaccination and that may be involved in the viral clearance. First, neutralizing antibody against the virus was monitored by plaque reduction assays. As shown in Figure 4a , the groups administered with pGEG.gB and pGEG.mIL-12 produced specific antibodies against HSV-1, while neutralizing antibodies were not significantly detected in the sera from the groups injected with a control plasmid (pGEG.luc) or saline. The administrations with pGEG.gB or pGEG.mIL-12 alone also induced inhibitory antibodies against HSV-1 plaque formation, but the degree of the inhibition was significantly lower than that obtained by the coadministration of the antigen and the cytokine genes. . All the mice survived lethal HSV-1 challenge (day 0), and they were killed on day 135 (lanes 1-4 represent each mouse). Eight mice were coadministered with 1 mg each of pGEG.gB and pGEG.mIL-10 (days À10 and À3). After lethal HSV-1 challenge (day 0), seven mice died by day 7, while one surviving mouse was killed on day 135 (lane 7). As control, a normal mouse was also killed (lane 5). DNA was obtained from the cerebrum (a and d), dorsal root ganglia (b and e) and trigeminal ganglia (c and f), and subjected to PCR using primers for HSV-1 gD (a-c) or b-globin (d-f) genes. Lane M, markers; lane 6, negative control without template DNA; lane 8, DNA extracted from HSV-1-infected Vero cells.
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The results were confirmed by another series of experiments in which the serum neutralizing antibodies were titrated. Consistent with the findings shown in Figure 4a , pGEG.gB plus pGEG.mIL-12 treatments resulted in an increase of neutralizing antibody titer, while a significant, but less drastic, elevation of the antibody titer was revealed in the pGEG.gB group (Figure 4b ). The analysis demonstrated that the intravascular gB genetic vaccine successfully induced a humoral immune response against HSV-1, while the IL-12 gene further significantly elevated the systemic antibody production.
pGEG.gB and pGEG.mIL-12 coadministration augmented CTL activity specific for gB
To examine whether cell-mediated immunity was also facilitated by the IL-12 pDNA adjuvant, we collected spleen cells from the genetically modified animals and measured CTL cytotoxic activity against P815 mastocytoma-derived transformants that had been engineered to express the HSV-1 gB gene (P815.gB) (P815 carries MHC class I of d haplotype). 13 Mice coadministered with pGEG.gB and pGEG.mIL-12 showed strong cytotoxic activity against the gB-positive target cells (Figure 5a ). The killing was revealed to be specific for the gB antigen, because the same effector cells failed to show any cytotoxicity against parental P815 cells lacking the viral antigen ( Figure 5b ). In sharp contrast, administration of pGEG.gB or pGEG.mIL-12 alone did not elicit a significant killing activity against P815.gB (Figure 5a ). The results demonstrated that the intravascular coadministration of 1 mg each of pGEG.gB and pGEG.mIL-12 synergistically elicited the gB gene-specific cell-mediated immune response that was not induced by 1 mg of the vaccine plasmid alone.
Another assay was performed to examine the proliferative response against HSV. As shown in Figure 5c , spleen cells obtained from the pGEG.gB-immunized mice showed significant proliferation in response to UV-inactivated HSV, to a comparable extent as that seen in the pGEG.gB plus pGEG.mIL-12-treated group.
Serum cytokines in gene-administered mice
The Th1 immune response was considered to play an important role in the gB pDNA-induced anti-HSV immunity (Figure 1) . Therefore, we examined whether the IL-12 pDNA adjuvant influenced systemic production of IFN-g, which is one of the most prominent cytokines mediating Th1 immune responses. The ELISA analysis demonstrated that the serum IFN-g concentration was significantly increased in mice genetically immunized with the gB antigen (Figure 6a ). The serum level of IFN-g was also elevated in mice administered with the IL-12 gene alone, while the coadministration of pGEG.gB and pGEG.mIL-12 resulted in a further drastic increase in the serum IFN-g level. The results suggest that the Th1 immune response was augmented in the gB gene-immunized mice when the IL-12 gene was employed as an adjuvant. In contrast, the gB plus IL-12 genetic administration failed to elevate the serum concentration of IL-4, the typical Th2 cytokine (Figure 6c ).
Contribution of soluble factors in anti-HSV protection
The combination treatment with gB and IL-12 genes resulted in a broad range of immune responses including antibody production, cytokine secretion and CTL activation. We performed adaptive transfer experiments to Genetic adjuvant for intravascular pDNA vaccine F-D Cui et al examine which component(s) may be responsible for protection against HSV. Sera and spleen cells were obtained from pDNA-administered mice and tested for the ability to bring resistance to the pathogen in naïve mice. Lethal HSV challenge killed all the mice that were injected with an aliquot of serum from mice that had received gB genetic immunization alone (Figure 7a ). In contrast, sera from mice coadministered with gB and IL-12 genes successfully protected 37% of mice from lethal viral infection, suggesting that soluble component(s) may contribute to the prophylactic immunity (Po0.05, pGEG.gB+pGEG.mIL-12 versus saline). Transplantation with spleen cells failed to ameliorate the survival rate of the recipient mice, regardless of the plasmids that had been given to the donor animals ( Figure 7b ).
Discussion
The present study demonstrates that intravascular coadministration of the gB gene and Th1 cytokine genes resulted in enhanced anti-HSV preventive immunity, In case gB or gD pDNA vaccine is administered into the skeletal muscle, 50-100 mg of the pDNA is applied so that mice are rendered resistant to lethal challenge of HSV. 3, 4, 7, 8 In our previous report, 5 mg of gB pDNA administered via an intravascular route allowed approximately 80% of mice to survive fatal HSV infection. 13 The present findings indicate that the coadministration of the IL-12 expression construct further reduced the dose of the vaccine that is required for induction of successful immune prevention. Indeed, 100% of mice escaped death by acute infection when 1 mg each of the vaccine and adjuvant plasmids was coinjected. The dose of the pDNA may be of great importance in practical applications of a gene vaccine, in relation to the potential side effects and cost of the vaccine treatment.
The intravascular immunization of 1 mg of the gB gene alone significantly elevated IL-12 and IFN-g concentrations in sera of mice, suggesting that a Th1 response can be triggered in the absence of exogenous IL-12 ( Figure 6 and our previous paper 13 ). The magnitude of the Th1 Mice were treated with the indicated plasmids or saline as in Figure 4a . On day 10, mice were killed, and the sera (a) and spleen cells (b) obtained from the mice were implanted into naïve mice, which subsequently received a lethal challenge with HSV-1. %Survival of the recipients is shown (n ¼ 8 in each group).
Genetic adjuvant for intravascular pDNA vaccine F-D Cui et al response may not be strong enough, since only a small proportion (16.7%) of the mice survived subsequent lethal HSV infection ( Figure 1 and our previous paper 13 ). The IL-12 genetic adjuvant further enhanced the Th1 response (Figure 6 ), improving the survival rate of virusinfected animals ( Figure 1) .
A considerable proportion (50%) of mice injected with IL-12 plasmid alone also became resistant to the viral challenge (Figure 1 ). This may be caused by direct immunomodulatory functions of IL-12 rather than specific immunity, because the IL-12 pDNA administrations induced IFN-g production (Figure 6a ) and proliferative response (Figure 5c ) but failed to elicit neutralizing antibody (Figure 4 ) or CTL activity ( Figure  5a ) at a detectable level. This concept is consistent with some previous reports demonstrating that administration of recombinant IL-12 significantly suppressed HSV infection in mice without any HSV-specific vaccination. 23, 24 IL-12 transgenic mice have been shown to be resistant to ocular HSV infection, 25 while IL-12 gene knockout mice were more susceptible to genital infection of HSV compared to wild-type animals. 26 Therefore, the powerful adjuvant effect of the cytokine gene in our system may be ascribed to both the augmentation of specific immunity triggered by the pDNA vaccine and nonspecific antiviral immunomodulatory functions of IL-12.
The adaptive transfer experiments shown in Figure 7 indicated that the prophylactic effect against the acute HSV infection can be transferred, at least in part, using soluble factors rather than lymphoid cell populations that were obtained from the mice injected with gB and IL-12 genes. In contrast, sera from the pGEG.gBimmunized mice did not successfully prolong the survival of the animals (Figure 7a ). The two groups of mice showed differences in titers of neutralizing antibody (1.9-fold) (Figure 4b ) as well as in concentrations of IFN-g (3.8-fold) and IL-12 (2.7-fold) (Figure 6a and b) , suggesting that these molecules played important roles in the prevention of lethal herpetic infection. Although such adaptive transfer experiments have not been performed in previous studies on HSV genetic vaccines, cumulative evidence has demonstrated that protection against lethal HSV infection was successfully achieved by intramuscular pDNA vaccines that were capable of inducing humoral response but not CTLs. 1, [3] [4] [5] 7, 8 The data shown in Figure 7 , however, do not indicate that CTLs did not play any role in antivirus defense, although it was shown that adaptive transfer of cell components failed to achieve viral clearance per se. Using gene knockout mice, Nass et al analyzed contribution of B cells, CD4 + and CD8 + T cells to the anti-HSV protection, clearly showing that all the populations are essential for the effective prophylactic immunity in their vaccine strategy. 8 In the rodent and human systems, both humoral and cellular responses have been shown to play crucial roles in the control of HSV infection. [27] [28] [29] [30] [31] [32] CTLs may be responsible for the recognition and elimination of infected cells, while antibodies may neutralize extracellular virus particles. In the meanwhile, cumulative evidence has demonstrated that natural killer cells are also involved in anti-HSV host defense. 33 The present procedure may provide promising means to regulate infectious diseases in clinical utility owing to the capability of inducing both the cellular and humoral immune responses. The system may also be quite useful in analyzing molecular and cellular mechanisms that lead to specific immune responses against genetically transduced antigens, providing useful information to devise novel and effective molecular vaccines and adjuvants.
Materials and methods

Plasmid vectors
pGEG.gB 13 contains the HSV-1 gB expression unit composed of the CAG promoter, 34 full-length gB-coding sequence and polyA additional signal, together with the Epstein-Barr virus (EBV) EBNA-1 gene and EBV oriP element. 35 pGEG.mIL -15, 36 pGEG.mIL-18, 37, 38 pGEG.mIL-21 36 and pGEG.luc 13, 37, 39 carry the mIL-15, mIL-18, mIL-21 and firefly luciferase genes, respectively. pGEG.mIL-12 37, 38, 40, 41 contains a bicistronic expression cassette with the murine IL-12 p35 and p40 genes (kindly provided by Dr Tahara, University of Tokyo). pGEG.mIL-10 was constructed by inserting the mouse IL-10 full-length cDNA (kindly provided by Dr KW Moore, DNAX Research Institute, CA, USA) into pGEG.4.
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Plasmids were purified using Qiagen Maxiprep Endo-free kits (Qiagen, Hilden, Germany).
Cells and virus
The Miyama strain of HSV-1 13, 42 was plaque-purified, grown on Vero cell monolayers and stored in aliquots at À801C. Titers were measured in Vero cells and expressed as plaque forming unit (PFU)/ml. The P815.gB cells were previously established by transfecting a gB gene expression plasmid into P815 (H-2 d ), 13 and the P815 and P815.gB cell lines were maintained in RPMI 1640 medium (Nacalai Tesque, Kyoto, Japan) supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum (FBS).
Mice, immunization and infection
Female Balb/c mice were purchased from Shimizu Laboratory Suppliers Co. Ltd (Kyoto, Japan). Mice (8-week-old) were intravenously injected with 1.6 ml plasmid solution (1 mg of a plasmid, or a mixture of 1 mg each of two plasmids) into the tail vein within 5 s. The immunization was performed two times at an interval of 7 days. As lethal challenge of HSV, mice were injected with 0.1 ml of viral suspension (10 5 PFU/ml) into the peritoneal cavity.
Detection of latent infection
Latent infection of HSV-1 was assessed as described. 43 Briefly, DNA was extracted from trigeminal ganglia, cerebrum, cerebellum and dorsal root ganglia of mice. A 1 mg portion of DNA was subjected to PCR analyses using the forward (5 0 -atccgaacgcagccccgctg-3 0 ) and reverse (5 0 -tctccgtccagtcgtttatcttc-3 0 ) primer pair corresponding to the HSV gD coding sequence, or another pair of primers (5 0 -ccaatctgctcacacaggatagag-3 0 and 5 0 -tgaggctgtccaagtgattcaggc-3 0 ) specific for the mouse b-globin gene (denaturation at 941C for 1 min, annealing at 601C for 1 min and extension at 721C for 1 min) (35 cycles). The PCR products were separated by gel electrophoresis through a 2% agarose gel, followed by ethidium bromide staining. 
Plaque reduction assays
The plaque reduction assays were performed as previously described. 13, 29 To assess the percent inhibition of plaque formation, sera were incubated at 561C for 30 min and diluted 1:10 in DMEM/2% heat-inactivated FBS. Aliquots of sera were transferred to duplicate wells of 96-well plates, into which 50 ml of HSV-1 suspension (4000 PFU/ml) was subsequently added. The plates were incubated overnight at 41C, before addition of guinea pig complement (Harlan, Loughborough, UK) diluted 1:4 in DMEM/2% heat-inactivated FBS. After incubation for 1 h at 371C, 50 ml of serum-free medium was added and the resultant mixture was used to infect confluent Vero cells in 24-well plates. After incubation for 1 h at 371C, cells were washed and overlaid with 1 ml of DMEM containing 5% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2% methylcellulose, followed by further incubation for 48 h under standard condition. Cells fixed with 2.5% glutaraldehyde were stained with 0.5% methylene blue for 30 min to visualize plaques. To evaluate the titers of the neutralizing antibodies, the heat-inactivated serum samples were diluted 1:10 in PBS, followed by preparation of serial two-fold dilutions (1:10 to 1:1280). The neutralization and plaque formation assays were performed as above. Neutralizing titer was defined as the reciprocal of the highest dilution of serum to produce 50% reduction in the number of plaques. 31 
Adaptive transfer
Mice were immunized with 1 mg of pDNA or saline on days 0 and 7, and spleen cells and sera were obtained on day 10. Mice (8-week-old) were intravenously injected with 0.2 ml of the sera into their tail vein and intraperitoneally challenged with HSV-1 as above. Other mice aged 8 weeks were intravenously injected into their tail vein with 1 Â 10 7 spleen cells, and 24 h later intraperitoneal HSV-1 inoculation was performed.
Statistical analyses
For the plaque assays, proliferation assay, cytotoxicity assay and ELISA, Student's t-test was used. The survival differences between groups were evaluated using the log-rank test.
